Addressing health disparities and transitions of care in eosinophilic gastrointestinal diseases.

Competing Interests: Disclosure statement Disclosure of potential conflict of interest: M. Chehade has served as a consultant for Regeneron, Allakos, Adare/Ellodi, Shire/Takeda, AstraZeneca, Sanofi, Bristol-Myers Squibb, Phathom, Recludix Pharma, and Nexstone Immunology and has received research funding from Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, Danone, and Bristol-Myers Squibb. E. T. Jensen receives or has received research support from Target RWE and Nutricia and consulting fees from Regeneron and Jazz Pharmaceuticals. The remaining author declares no relevant conflicts of interest.